JP2020528082A5 - - Google Patents

Download PDF

Info

Publication number
JP2020528082A5
JP2020528082A5 JP2020524719A JP2020524719A JP2020528082A5 JP 2020528082 A5 JP2020528082 A5 JP 2020528082A5 JP 2020524719 A JP2020524719 A JP 2020524719A JP 2020524719 A JP2020524719 A JP 2020524719A JP 2020528082 A5 JP2020528082 A5 JP 2020528082A5
Authority
JP
Japan
Prior art keywords
seq
cpp
sequence listing
therapeutic agent
rpe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/042410 external-priority patent/WO2019018350A1/en
Publication of JP2020528082A publication Critical patent/JP2020528082A/ja
Publication of JP2020528082A5 publication Critical patent/JP2020528082A5/ja
Pending legal-status Critical Current

Links

JP2020524719A 2017-07-17 2018-07-17 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 Pending JP2020528082A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533231P 2017-07-17 2017-07-17
US62/533,231 2017-07-17
PCT/US2018/042410 WO2019018350A1 (en) 2017-07-17 2018-07-17 TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES

Publications (2)

Publication Number Publication Date
JP2020528082A JP2020528082A (ja) 2020-09-17
JP2020528082A5 true JP2020528082A5 (cg-RX-API-DMAC10.html) 2021-10-21

Family

ID=63104068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524719A Pending JP2020528082A (ja) 2017-07-17 2018-07-17 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達

Country Status (8)

Country Link
US (2) US10905770B2 (cg-RX-API-DMAC10.html)
EP (1) EP3654941A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020528082A (cg-RX-API-DMAC10.html)
CN (1) CN112996486A (cg-RX-API-DMAC10.html)
AU (1) AU2018302022A1 (cg-RX-API-DMAC10.html)
CA (1) CA3070241A1 (cg-RX-API-DMAC10.html)
IL (1) IL272105A (cg-RX-API-DMAC10.html)
WO (1) WO2019018350A1 (cg-RX-API-DMAC10.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339367A (zh) * 2018-04-02 2019-10-18 北京键凯科技股份有限公司 一种具有靶向性的穿膜肽-多臂聚乙二醇-药物偶联物及其应用
US11136381B2 (en) 2018-04-03 2021-10-05 Ngm Biopharmaceuticals, Inc. Anti-C3 antibodies
TW202009013A (zh) * 2018-08-14 2020-03-01 優你康光學股份有限公司 具有功能性成分的隱形眼鏡及其產品
US12115212B2 (en) * 2019-01-18 2024-10-15 L & J Bio Co., Ltd. Methods of decreasing amyloid beta (Aβ) plaque deposition and hyperphosphorylated tau plaque deposition in Alzheimer's disease using a cystatin C fusion protein
GB201900728D0 (en) * 2019-01-18 2019-03-06 Univ Birmingham Drug delivery system
JP2022524078A (ja) * 2019-03-08 2022-04-27 ラ ファーマシューティカルズ インコーポレイテッド 深部組織浸透性ｃ５阻害剤としてのジルコプラン
ES3072908T3 (en) * 2019-04-08 2026-07-06 Biocryst Pharm Inc Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
US20220251605A1 (en) * 2019-06-14 2022-08-11 The Brigham And Women's Hospital, Inc. Membrane attack complexes and uses thereof
JP7664239B2 (ja) * 2019-10-30 2025-04-17 パフューズ セラピューティクス， インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置
CA3157394A1 (en) 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
CA3168810A1 (en) 2020-02-06 2021-08-12 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
JP2023515827A (ja) * 2020-02-28 2023-04-14 ノースウェスタン ユニバーシティ 房水流出を高め、眼圧を減少させる方法
US20230173024A1 (en) * 2020-04-01 2023-06-08 The Trustees Of The University Of Pennsylvania Factor b inhibitors and uses thereof
US11754753B2 (en) 2020-04-27 2023-09-12 Coopervision International Limited Antioxidant contact lens
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
CN111671922B (zh) * 2020-07-23 2023-03-21 四川大学华西医院 两亲性梳形嵌段接枝共聚物基超声造影剂及其制备方法
CN114073774A (zh) * 2020-08-17 2022-02-22 奥朗生物医药有限公司 药物和野生型穿膜肽衍生物的组合物
US11389431B2 (en) 2020-09-09 2022-07-19 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
KR102556731B1 (ko) * 2020-09-29 2023-07-21 주식회사 젠센 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
AU2021368859A1 (en) * 2020-10-28 2023-06-22 The Florey Institute Of Neuroscience And Mental Health Peptide-based delivery of agents
CN114790225B (zh) * 2021-01-26 2024-09-10 清华大学 一种新型内体逃逸肽及其应用
WO2022192879A1 (en) * 2021-03-09 2022-09-15 Florida State University Research Foundation, Inc. Lipid vesicle-mediated delivery to cells
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
US20240216520A1 (en) * 2021-04-06 2024-07-04 University Of South Florida Peptide-small interfering rna-hyaluronic acid nanoparticles and methods of use thereof
BR112023022705A2 (pt) * 2021-04-30 2024-01-16 Perfuse Therapeutics Inc Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
CN117295520A (zh) * 2021-04-30 2023-12-26 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
CN113332450B (zh) * 2021-05-11 2023-08-04 铜仁学院 一种眼部给药递释系统氧化锌纳米粒的制备方法及其使用方法和应用
JP2024520496A (ja) * 2021-05-28 2024-05-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 加齢黄斑変性に続発する地図状萎縮の治療のための補体ｄ因子阻害剤の使用
CN113476587B (zh) * 2021-07-19 2022-07-12 河南大学 一种脑靶向的神经保护剂ss31-ha-rt及其制备方法和应用
CN113925966B (zh) * 2021-09-17 2022-10-04 西安电子科技大学 快速响应型细胞核靶向纳米诊疗探针的制备方法
CN114404429B (zh) * 2021-11-30 2023-06-30 重庆医科大学附属第二医院 一种纳米银修饰的单宁酸-铁网络的载药纳米复合物及其制备方法和逆转肿瘤耐药应用
KR102795182B1 (ko) * 2022-02-18 2025-04-15 (주)메디톡스 탈모 치료 또는 발모 촉진 활성을 갖는 폴리펩티드 및 그의 용도
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
US20250230208A1 (en) 2022-04-06 2025-07-17 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN116444678B (zh) * 2022-10-18 2024-02-02 百葵锐(深圳)生物科技有限公司 一种具有真菌抗菌抑菌性能的新型多肽
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis
WO2024156871A1 (en) * 2023-01-27 2024-08-02 Glasspearl Oü Mixtures of lipid nanoparticles and cell penetrating peptides
WO2024160819A1 (en) 2023-01-30 2024-08-08 Consorcio Centro De Investigación Biomédica En Red Nanoparticles with antibodies for ocular treatment
WO2024178368A2 (en) * 2023-02-23 2024-08-29 Ohio State Innovation Foundation Therapeutic protein combinations
CN116270974B (zh) * 2023-03-09 2024-03-12 湖南大学 一种组合物、阿柏西普递送系统和制备方法
TWI877652B (zh) * 2023-06-14 2025-03-21 長庚大學 眼用藥物遞送載體及其應用
WO2025093129A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) * 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025117721A1 (en) * 2023-11-27 2025-06-05 Massachusetts Institute Of Technology Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain
WO2025128821A1 (en) * 2023-12-12 2025-06-19 Juvena Therapeutics, Inc. Compositions and methods for adp-ribosylation factor molecular trafficking
WO2025147589A1 (en) * 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders
WO2025212745A1 (en) * 2024-04-04 2025-10-09 University Of Massachusetts Engineered adeno-associated virus (aav) capsid protein and uses thereof
CN118290598B (zh) * 2024-05-29 2024-09-27 深圳柏垠生物科技有限公司 重组纤连蛋白及其制备方法和应用
WO2026026844A1 (zh) * 2024-07-31 2026-02-05 苏州百迈生物医药有限公司 一种两亲性药物载体及其在眼部药物递送中的应用
WO2026033482A1 (en) * 2024-08-08 2026-02-12 Universita' Degli Studi Di Torino Therapeutic contact lenses loaded with mucin-based nanoparticles
CN118995345B (zh) * 2024-08-09 2025-09-26 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
WO2026034435A1 (ja) * 2024-08-09 2026-02-12 東亞合成株式会社 ペプチドフラグメント及びその利用
WO2025218147A1 (zh) * 2024-08-09 2025-10-23 山西医科大学 一种抑制角膜缺氧损伤和角膜新生血管的隐形眼镜护理液及其制备方法
CN119746027A (zh) * 2025-01-10 2025-04-04 山东济肽生物科技有限公司 多肽组合物的应用及治疗衰老相关皮肤病的组合物
CN119792574B (zh) * 2025-01-10 2025-12-19 宁夏医科大学 一种仿生plga复合纳米材料及其制备方法与应用
CN121253831B (zh) * 2025-10-31 2026-07-14 宁波大学附属人民医院 一种用于检测rvo-me抗vegf治疗分型的生物标志物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548114C2 (de) 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
CA2530407A1 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
AU2009240747A1 (en) 2008-04-22 2009-10-29 Merck Frosst Canada Ltd Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
RU2012147589A (ru) 2010-04-09 2014-05-20 Мерк Шарп Энд Домэ Корп. Новые отдельные химические структурные единицы и способы доставки олигонуклеотидов
KR20130083843A (ko) 2010-06-24 2013-07-23 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 디펩티드 연결된 약제
BR112014010806A2 (pt) 2011-11-03 2017-05-02 Bayer Ip Gmbh ligadores à base de tirosina para a ligação reversível de peptídeos
WO2013086493A1 (en) 2011-12-09 2013-06-13 The Children's Hospital Of Philadelphia Compositions and methods for the generation of activated protein c and methods of use thereof
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
GB201401453D0 (en) 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201403268D0 (en) 2014-02-25 2014-04-09 Univ Birmingham Antimicrobial surface
CN117582516A (zh) 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
DK3362063T3 (da) * 2015-10-14 2023-04-03 Massachusetts Eye & Ear Infirmary Højdosisstatiner til aldersrelateret makuladegeneration
CN106668860B (zh) * 2015-11-09 2019-11-22 烟台大学 靶向眼后段的递药系统及其制剂和制备方法
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents

Similar Documents

Publication Publication Date Title
US10905770B2 (en) Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
US20180296525A1 (en) Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
US20210138034A1 (en) Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
JP2020514407A (ja) アポリポプロテイン模倣物を用いる加齢黄斑変性と他の眼疾患の治療
US11413322B2 (en) Immunotherapy for angiogenic disease
ES2644016T3 (es) Péptidos para su uso en el tratamiento tópico de enfermedades neurodegenerativas retinianas, en particular en estadios tempranos de retinopatía diabética y otras enfermedades retinianas en las que la neurodegeneración desempeña un papel esencial
TWI581801B (zh) 治療血管新生相關之眼疾之組合物及方法
JP6725940B2 (ja) 抗血管新生活性を有するシンデカン−２のフラグメント
EP3224278A1 (en) Methods and formulations for treating vascular eye diseases
EP3238746B1 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
US20160022769A1 (en) Compostions and methods for treating retinal disease
CN109937053A (zh) 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物
US20240299564A1 (en) Peptide carriers and delivery to the eye of a subject
JP2020518675A (ja) ノリン誘発性の遺伝子発現および疾患を処置するためのその使用
JP6944463B2 (ja) 眼疾患の治療のための組成物及び方法
WO2022125548A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
CN107771077A (zh) 用于治疗轴突损伤的小白菊内酯及其衍生物
KR20180102091A (ko) 당뇨병의 치료를 위한 약제학적 제제
HK40011780A (en) Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics
HK1245149B (en) Wt1 immunotherapy for intraocular angiogenic disease